Articles tagged with Cancer Medication
A new cancer drug, brentuximab vedotin (Adcetris), has dramatically improved survival rates for Hodgkin lymphoma patients who have failed other treatments. In a multi-center study, 65% of patients were alive at 24 months, and 25% had no progression of the disease.
The US government is developing medical countermeasures against nuclear threats, including acute radiation syndrome (ARS). Several companies are working on adapting existing drugs and creating new compounds to treat ARS symptoms and remove radioactive particles from the body.
Researchers at Moffitt Cancer Center tested a 2-drug combination of sirolimus and tacrolimus to prevent acute grades of graft vs. host disease after blood cell transplantation, finding it more effective than another combination in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD.
A study by the University of Kentucky Markey Cancer Center found that cancer patients experienced significant improvements in pain, stress, and nausea after one Jin Shin Jyutsu session. The study included 159 patients who reported a mean decrease of three points for stress and two points for both pain and nausea.
A systematic review of seven studies involving over 32,400 patients found that metformin reduced the risk of any type of cancer by 38% compared to those not taking the medication. The benefits were seen in colon and breast cancer, but not pancreatic cancer.
Researchers at Moffitt Cancer Center and colleagues have tested deferasirox as a treatment for myelodysplastic syndrome (MDS), a blood-related malignancy that affects the ineffective production of blood cells. Deferasirox reduced iron levels by 23% in 53% of patients, showing promising results for this type of cancer.
Researchers found that cancers with disorganized traffic systems result in lower survival rates and are more difficult to treat. A mathematical equation could help doctors determine the best course of treatment by identifying the complexity of each cancer type.
Researchers at Nationwide Children's Hospital have created a new drug to target osteosarcoma, the most common bone tumor in children, using a modified version of Celebrex. The drug, 8A, selectively inhibits the STAT3 pathway, which is crucial for tumor formation and cancer progression.
Researchers at UC San Diego have identified a new signal transduction pathway in alternative RNA splicing, which could lead to novel cancer drugs. The SRPK kinase plays a central role in regulating VEGF and controlling tumor growth.
Weill Cornell researchers devise innovative boxer-like strategy to deliver one-two punch to multiple myeloma by weakening defenses and then killing cancer cells. The approach, using two anti-cancer drugs, shows potential for treating other tumor types.
A recent study published in Gynecologic Oncology reveals that widely available cell lines are often misidentified or contaminated, leading to faulty cancer science. Researchers suggest verifying cell lines as a prerequisite for publishing, and the team is working to build a database to help identify mismatched cell lines.
Researchers uncovered surprises in genes previously thought uninvolved in breast cancer, revealing the complex drivers of this leading cause of cancer death. The study found novel fusion gene MAGI1-AKT3, which acts as an oncogene and offers new therapy targets.
Researchers have created a dynamic 3D computer model of the human P-glycoprotein, which is thought to contribute to chemotherapy failure in many recurring cancers. The model enables scientists to virtually screen over 8 million potential drug compounds to find one that can help stop chemotherapy resistance.
Researchers found that the SETDB1 gene accelerates cancer progression in zebrafish with human BRAF mutations, similar to its effect in humans. The study suggests that SETDB1 may be a master regulator of melanoma and could lead to new treatments.
Researchers discovered a new mechanism that promotes lung cancer growth and survival by regulating autophagy, a complex process initiated under stressful conditions. The protein BI-1 was found to protect lung cancer cells and suppress tumor growth by modulating intracellular signals.
A new approach to drug design, called the magic shotgun method, promises to help identify future cancer drugs that are more effective and have fewer side effects. This approach sifting through the known universe of chemicals to find special molecules that broadly disrupt the whole disease process.
The Pew Scholars Program identifies and invests in talented researchers, enabling them to pursue innovative research and take calculated risks. This year's class of scholars is exploring various human health issues.
A Phase 2 clinical trial is underway to test the effectiveness and safety of INNO-206 in treating advanced pancreatic ductual adenocarcinomas. The drug works like a Trojan Horse by being prepared in albumin, which pancreatic cancer cells prefer, allowing it to deliver cancer-killing agents directly to the tumor.
A new immune approach to fighting some cancers has shown promise, with 20-25% of heavily pre-treated patients responding to BMS-936558. The treatment specifically blocks programmed cell death 1 (PD-1), a key immune checkpoint receptor.
The new skin cancer drug vismodegib was approved by the FDA in 2012 for treating locally advanced and metastatic basal cell carcinomas. It blocks the Hedgehog signaling pathway and has shown promising results for patients with inherited genetic susceptibility.
The Damon Runyon Cancer Research Foundation awarded $3.3 million to eight promising young clinical investigators, focusing on breast cancer and brain tumors.
Research studies presented at the American Society of Clinical Oncology meeting showed promising advances in targeted therapy for various cancers. Additionally, clinical trial results indicated that intermittent hormonal therapy may shorten survival for certain prostate cancer patients while improving quality of life.
Researchers at the University of Kentucky have developed two new ruthenium complexes that are up to 200 times more toxic and three times more potent than cisplatin against tumor cells. These complexes become activated when exposed to light, reducing their impact on healthy cells.
Researchers developed a multi-target approach to treat tumors using fruit flies, creating an investigational compound AD80 that targets multiple cancer genes. Tested in mouse models, AD80 proved far more effective and less toxic than standard cancer drugs.
A new study published in the New England Journal of Medicine shows that vismodegib is effective in treating basal cell carcinoma, a common cancer caused by sun exposure. Researchers found that patients with Gorlin syndrome who took vismodegib developed an average of two new tumors per year, compared to 29 in those taking placebo.
Researchers have shown that CCR5 antagonists can prevent the migration and spread of breast cancer cells. Blocking CCR5 also reduces the formation of pulmonary metastases in mice with basal breast cancer, suggesting a new treatment option.
New nanomedicine cancer treatments aim to focus on tumor cells while sparing healthy tissue, potentially reducing severe side effects. These nanoparticle-based medications can deliver anti-cancer drugs directly to tumors through tiny blood vessel passages.
A new study led by University of Rochester Medical Center researcher Barbara L. Asselin shows that giving a cardio-protective drug during cancer treatment may prevent damage to the hearts of childhood leukemia survivors. The study found that the drug Zinecard significantly reduced heart problems and damage in patients who received it.
Researchers found that childhood cancer survivors develop secondary gastrointestinal cancers at a rate nearly five times higher than the general population. The study's lead author suggests implementing earlier screening guidelines for this population, particularly those with increased risk factors.
A new breast cancer treatment, trastuzumab emtansine (T-DM1), has shown significant improvements over standard therapy in keeping advanced tumors from progressing, with fewer and less harsh side effects.
A seventeen-year study led by SWOG found that intermittent hormone therapy for metastatic prostate cancer is inferior to continuous therapy, with overall survival times shorter for many patients. The treatment approach was also shown to have varying effects on different disease stages.
A large survey by the SWOG cancer research cooperative group found that lower-income cancer patients were less likely to participate in clinical trials than those with higher incomes. This disparity is concerning, as it may limit their access to cutting-edge treatments and impact the accuracy of trial results.
Researchers have identified androgen receptors as a key target for treating breast cancer, leading to the development of enzalutamide as a potential new therapy. The study suggests that blocking these receptors can inhibit cancer growth, offering new hope for patients with hormone-dependent breast cancers.
A new medication, abiraterone acetate, has been shown to slow the spread of metastatic prostate cancer while maintaining quality of life in patients. The study involved 1,088 men and demonstrated improved survival and reduced need for chemotherapy and pain medications.
Two experimental drugs targeting the PD-1/PD-L1 pathway showed promising early results in patients with advanced non-small cell lung, melanoma, and kidney cancers. Significant tumor shrinkage was seen in patients treated with these therapies.
The study found that two tumor suppressor genes, KLF6 and FOXO1, can disrupt overactive EGFR signaling. By targeting the FOXO1/KLF6 axis, researchers were able to restore effectiveness of anti-EGFR drugs like erlotinib and reduce tumor growth.
Researchers at UW-Madison develop combination therapy that knocks out signaling of multiple EGFR family members in brain-cancer cells, inhibiting growth and evasion of current therapies. The study's lead author reports success with lapatinib treatment, a novel drug approved by the FDA.
Researchers developed a more effective way to treat gynecologic cancers using stereotactic body radiotherapy (SBRT), which targets well-defined tumors and limits the effect of radiation on healthy tissues. The new method significantly reduces treatment time, from five weeks to three days.
A study found that combining lapatinib and pazopanib did not improve outcomes for patients with inflammatory breast cancer, despite increased side effects. Lapatinib was shown to be an effective treatment option for women with this disease.
A team of researchers has discovered a novel combination of two previously approved FDA drugs that can be used to treat advanced/late stage lung cancer by activating key genes involved in the disease. The treatment targets a pathway to accelerate cancer diagnosis and treatment.
Researchers discovered that GPR21 inhibition improves insulin sensitivity and energy expenditure in mice with obesity. The absence of GPR21 also reduces inflammation and decreases body weight under normal diet conditions. Additionally, another study found that FOXO1 plays a critical role in regulating energy balance and glucose metabol...
The US Food and Drug Administration (FDA) is issuing recommendations for breast cancer trials that would substantially accelerate patient access to new medications. The new regulatory guidelines are based in part on groundbreaking, national breast cancer research led by UCSF.
Researchers at Ohio State University have identified a 'life-and-death' molecule on the surface of chronic leukemia cells that targets CD37. The finding could lead to more effective therapy for CLL, an as yet incurable cancer that occurs in over 16,000 Americans annually.
A new study suggests that genetic variations can predict a person's response to drug treatments for nicotine addiction, with those at high-risk of heavy smoking showing the greatest response to pharmacologic therapy.
A study by Weizmann Institute scientists reveals that leukemia recurrence is often caused by 'cancer stem cells' that divide slowly, evading chemotherapy drugs. These cells can give rise to new rapidly-dividing cancer cells, making them a key target for new treatment approaches.
Researchers have identified a biomarker for advanced bile duct fibrosis and bile duct cancer caused by the Asian Liver Fluke, allowing for earlier detection and potentially saving lives. The Thai Ministry of Health has implemented testing for this biomarker in endemic regions to identify individuals at risk.
A new study suggests that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin can decrease the risk of squamous cell carcinoma and malignant melanoma. The findings indicate a potential cancer-protective effect of NSAID use, which should be considered when discussing benefits and harms.
Researchers at McMaster University have discovered a drug, thioridazine, that kills cancer stem cells in humans while avoiding toxic side effects of conventional treatments. The study holds promise for new strategies and discovery pipelines for developing anticancer drugs.
Researchers discovered an anti-psychotic drug, thioridazine, that selectively targets and exhausts cancer stem cells, leading to improved survival rates in leukemia patients. The compound works by encouraging cancer stem cells to differentiate into less threatening cell types.
Researchers identified a single gene AUF1 controlling inflammation, aging and cancer. The study found that deleting the gene led to accelerated aging.
A study conducted by TGen-Scottsdale Healthcare analyzed the patient's tumor and normal DNA to identify significant gene mutations that could be targeted for therapy. The analysis provided clues to possible precision medicine treatment of rare nasal tract cancer.
Scientists at IDIBELL have found a new checkpoint in cell cycle control through the joint action of two proteins, RPL11 and RPL5, which disrupts ribosomal biogenesis. This leads to the activation of p53 protein and cell cycle arrest.
A study led by Fred Hutchinson Cancer Center researchers found a novel approach to inhibit cancer cells using an inexpensive 'orphan drug', originally developed for sleep disorders. The compound, CSNK 1 epsilon, kills cancer cells while sparing normal tissue, offering new hope for treating Myc-driven cancers.
Massachusetts General Hospital surgeons developed a new technique using cryopreserved aortas to reconstruct the larynx, allowing patients to maintain voice and swallowing function without immunosuppressive medications. The procedure was successful in removing postoperative tracheotomy tubes and resuming breathing normally.
A team of scientists has developed a new strategy to reactivate genes that cause cancer tumors to shrink and die. The researchers found that inhibiting the PAD4 enzyme can effectively target unhealthy, cancerous tissue without damaging healthy tissues.
Researchers created a new anti-cancer drug named BP-1-102 that targets the Stat3 protein, which triggers cancer development in various types. The drug remains effective even when administered orally, unlike most current treatments requiring intravenous injection.
Researchers have identified a biomarker that can predict which patients will benefit from bevacizumab treatment. The variant in DNA found in blood samples of cancer patients showed predictive value for treatment with bevacizumab, potentially allowing for patient-tailored use of the drug and increasing the chances of survival.
Researchers have discovered biomarkers that predict response to treatment and proposed therapeutic solutions for patients who do not respond well. The study identifies the molecular mechanisms determining patients' response to certain drugs used in clinical trials.
A study published in Cancer Research found that RalA and RalB proteins are associated with aggressive cancer characteristics in human tumors. The signature of genes changed by these proteins predicts poor outcomes. Removing these proteins from cancer cells may stop the genetic changes that cause aggressive cancer.
A phase I clinical trial combining temsirolimus and capecitabine demonstrates promising evidence of disease control in advanced malignancies. The study shows that the combination can be given safely to patients, with a positive survival trend observed.